Advirna is a new private biotechnology company developing innovative solutions for efficient delivery of polynucleotides in vivo. Our technology platform (self-deliverable RNAi) is based on the recent breakthrough in biology known as RNA interference (RNAi). This discovery opened a possibility to specifically regulate activity of genes inside a living cell. Advirna’s proprietary RNAi platform based on self-deliverable RNAi technology has broad applications in Life Sciences. Self-deliverable RNAi provides researchers with new and efficient tools to specifically knock-down genes in living cells (both in vitro and in vivo) as well as to develop a pipeline of drug products to treat a wide array of human diseases.